The Dezhou Association for Science and Technology organized the Dezhou Enterprise "Innovation Talent" promotion activity, aiming to select and cultivate technological innovation talents in enterprises. In the 2023 annual selection, our senior vice general manager Liu Baofeng was awarded this title.

As the Senior Vice General Manager of the company, Liu Baofeng is committed to promoting the construction of the company's technological capabilities and business expansion. In terms of technology platform construction, in response to the long-term intravenous infusion demand for drugs with short clinical half-life and high toxicity, the company has established a continuous intravenous infusion technology for conscious rats and dogs (lasting for 3 months), and has completed non clinical safety evaluations of 2 drugs using this technology platform.

Clinical long -term medication safety evaluation platform

The company has established a molecular biology laboratory and biological macromolecule detection methods, and the related technology platform can be used for non clinical evaluation of nucleic acid drugs, therapeutic vaccines, and preventive vaccines. As of now, the company has completed the evaluation of one small nucleic acid therapy drug, five therapeutic vaccines, and multiple preventive vaccines using this platform.

Pathological diagnosis is an important method for determining drug toxicity. The company has developed special sampling techniques and related technologies such as immunohistochemistry staining based on market demand. In 2022, the company obtained the "Toxicity Pathology Examination" capability verification certificate organized by the China National Accreditation Service for Conformity Assessment (CNAS).


Introduction to Liu Baofeng:
     Liu Baofeng, senior deputy general manager of Shandong Xinbo Drug Research Co., Ltd., deputy director of the Drug Safety Evaluation Research Center, executive member of the Safety Evaluation Professional Committee of the Chinese Academy of Chinese Medicine, member of the Shandong Poison Society, and executive director of the Shandong Experimental Animal Society.Liu Baofeng, Senior Vice General Manager of Shandong Xinbo Pharmaceutical Research Co., Ltd., Deputy Director of the Drug Safety Evaluation Research Center, Executive Member of the Safety Evaluation Professional Committee of the Chinese Society of Traditional Chinese Medicine, Member of the Shandong Toxicology Society, and Executive Director of the Shandong Experimental Animal Society.

I have been engaged in drug safety evaluation work for 21 years, and have led and completed non clinical safety evaluations of more than 30 Class 1 new chemical drugs, more than 40 new traditional Chinese medicine drugs, more than 400 generic drugs, and more than 50 vaccines. I also participated in the writing of the book "Drug Vigilance and Safety Evaluation". During the COVID-19, according to the characteristics of different COVID-19 vaccines, it designed corresponding non clinical safety evaluation research programs, and completed the related evaluation work in a relatively short time. Up to now, more than 30 non clinical safety evaluation studies of COVID-19 vaccine have been completed, and many have obtained clinical trial permits.

Has won the first prize of Shandong Province Enterprise Technology Innovation Award for Excellent Achievements, the second prize of the 15th Dezhou Natural Science Excellent Academic Achievement Award, and the third prize of Dezhou Science Progress Award.
I have been engaged in drug safety evaluation for 21 years. I have accumulated rich research experience in the safety evaluation of innovative drugs such as chemical drugs, Chinese medicine and biological products. Multiple generic drugs and more than 50 vaccines clinical safety evaluation work, and participated in the writing of "Drug Alert and Safety Evaluation". Especially since the outbreak of the new crown epidemic, through its own rich experience, targeted clinical safety evaluation and design is conducted for the characteristics of different new crown vaccines, and the vaccine evaluation is completed within the shortest experimental cycle. Essence As of now, a total of more than 30 clinical safety evaluations of more than 30 new crown vaccines have been completed, and many of them have obtained clinical permits and have entered clinical trials. He has won the "First Prize of the Excellent Achievement of the Shandong Enterprise Technology Innovation Award", "2018-2020, the second prize of the 15th Natural Science Outstanding Academic Achievement Award of Natural Sciences in Texas", "the third prize of the Texas Science Progress Award" Honor.